ACTUS-101 by Asklepios BioPharmaceutical for Pompe Disease: Likelihood of Approval

Figure 1: M&A deal volume and value globally from 2021 to Q1 2024. Credit: GlobalData. Mergers and acquisitions (M&As) in the biopharmaceutical industry involving companies

Why did a 51-year-old man with no significant medical history suddenly develop slurred speech and left-sided symptoms — weakness in his arm, a drooping eyebrow

John­son & John­son scored a la­bel ex­pan­sion for Ry­bre­vant in com­bi­na­tion with the new­ly-ap­proved Laz­cluze to treat cer­tain first-line lung can­cer pa­tients, putting it in